Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Benign Vulval Skin Conditions (313)
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

Benign Vulval Skin Conditions (313)

Warning

Please report any inaccuracies or issues with this guideline using our online form

This guideline is to help with initial assessment and care of women with vulval disorders, with advice on when to refer to the specialist multidisciplinary team.

Commonest presentation is with non-specific symptoms such as pruritus, pain and changes in skin colour and texture.

History

See Appendix 1 for useful questions

This should include the following:

  1. Self medication or previous inadequate or inappropriate treatments which may contribute to symptoms
  2. Cervical cytology, smoking and immune deficiency especially for women with suspected vulval intraepithelial neoplasia (VIN)
  3. Contact with potential allergens or irritants. The most common relevant allergens are cosmetics, medicaments and preservatives. Others include fragrances, rubber, textile dyes, washing powder, fabric conditioners, sanitary towels, panty liners and synthetic underwear. Secondary sensitisation to multiple products is common.
  4. Personal or family history of autoimmune conditions e.g. type 1 diabetes, arthritis, thyroid disease, pernicious anaemia, alopecia, vitiligo
  5. Personal or family history of atopic conditions
  6. History of skin conditions elsewhere on the body – skin and/or mucous membranes
  7. Urinary and/or faecal incontinence. Damage to barrier function or secondary dermatitis exacerbated by moisture, temperature and friction
  8. Impact on sexual function
  9. Drug history to exclude fixed drug eruptions ( e.g. nicorandil )

Examination and Investigations

  1. Perform under a good light, with adequate exposure including peri-anal skin
  2. No necessity for colposcopy or acetic acid, except for examination of VIN
  3. Ask patient to show the affected area first
  4. Consider extra-genital sites: scalp, elbows, knees, nails, oral mucosa
  5. Consider infestations such as scabies, lice, ringworm, pinworm, threadworm
  6. No need to test for auto-immune conditions without a clinical indication
  7. Consider serum ferritin in women with vulval dermatitis. Correction of iron-deficiency anaemia or low serum ferritin can relieve vulval symptoms
  8. STI screen if clinically indicated
  9. Biopsy:
    1. If the woman fails to respond to treatment
    2. There is suspicion of VIN or cancer (20-22% of VIN have invasive cancer on biopsy)
    3. There are atypical or suspicious areas

Benign causes of vulval symptoms include:

Lichen simplex chronicus or Chronic vulval dermatitis: a common inflammatory skin condition, especially in those with sensitive skin, dermatitis or eczema. Severe,intractable pruritis, especially at night. There may be erythema and swelling with discrete areas of thickening and lichenification, especially with scratching. Sometimes linked to stress or low body iron stores.  

Vulval candidiasis: diabetes, obesity and antibiotic use may be contributory. Prolonged topical or oral antifungal therapy may be necessary.

Vulval psoriasis: Involves vulval skin but not vaginal mucosa. The appearance often differs from the typical scale of non-genital sites. It often appears as smooth, non-scaly red or pink discrete lesions.  

Atrophic vulvovaginitis: In premenarchal girls and postmenopausal women. See menopause protocol.

Lichen sclerosus. Skin often pale and affected in a ‘figure-of-eight’ pattern. Inflammation can result in adhesions, fusion and resorption of the labia. See Lichen sclerosus protocol.

Lichen planus: Usually affects mucosal surfaces and commonly seen on oral mucosa. Presents with flat-topped violaceous purpuric plaques and papules with a fine white reticular pattern (Wickham striae) but can be erosive and painful. Erosive LP appears as a well demarcated, glazed erythema around the introitus. Aetiology is unknown, but may be autoimmune. It can affect all ages and not linked to hormonal status. Consider referral to vulval clinic.

Vulval Crohns disease: Vulval involvement by direct extension from involved bowel or metastatic granulomas, rarely preceding or without known bowel disease. Vulva often swollen and oedematous with granulomas, abscesses, ulceration or draining sinuses. Refer to vulval clinic.

Vulvodynia: see vulval pain protocol

Treatment

General life-style advice is essential in the management of any vulval skin condition. This includes smoking cessation and avoidance of common allergens and irritants (see appendix 2 Vulval skin Care).

The mainstay of treatment for Lichen simplex chronicus is general vulval care and the use of soap substitutes and emollients. Antihistamines or antipruritics may be helpful, especially if sleep is disturbed. Other options include Dermacool or ICL (ichthammol calamine lotion). Moderate or ultrapotent topical steroids may be helpful to break the itch-scratch cycle.

Treatment will depend on the specific diagnosis and should be discussed with a senior clinician.

Women with vulval psoriasis should be followed up in dermatology or vulval clinic.

Clobetasol propionate (eg Dermovate) is the most potent topical steroid available. The ointment preparation is preferred to the cream as it provides better skin contact and is less likely to cause irritation – creams contain propylene glycol, parabens and fragrances. See Appendix 3 for Regime of Steroid Use

Emollients should be prescribed to moisturise, sooth and act as a protective barrier. Women should be advised to leave an interval of at least 30 minutes between emollients and applying other treatments. They can also be stored in the fridge for symptomatic relief. Examples include Dermol 500, Diprobase, Doublebase, Emulsifying ointment, Epaderm, Aqueous cream.

Referral Criteria to Tertiary Vulval Clinic at Stobhill

  • Women who have not responded to standard treatment for their vulval condition
  • Women who are requiring frequent prolonged courses of ultra-potent steroids
  • Women whose disease is steroid resistant
  • Women whose symptoms are poorly controlled
  • Women with rare vulval conditions

Appendix 1: Patient Questionnaire

You have been referred to this clinic with a skin problem. It would be helpful if you could complete this questionnaire before you are seen. This will help to identify any factors that may be causing or aggravating your skin problem. This will be discussed with the doctor, but you may want to add additional notes if you feel it will help you to remember any important information.

YES

NO 

SOMETIMES

Do you take a bath?

Do you take a shower?

Do you wash your hair in the bath or shower?

What do you wash over all with?

What do you wash the vulva area with?

Do you use moist skin wipes in the vulval area?

Do you use talcum powder in the vulval area?

Do you use antiseptic in the bath?

What do you use to wash your clothes?

Do you use a fabric softener/conditioner?

What type/material underwear do you usually wear?

Do you wear dark coloured underwear?

What colour toilet paper do you use?

Do you use tampons?

Do you use sanitary towels?

Do you use panty liners?

Do you use incontinence pads?

Do you use condoms?

The following questions relate to your own health.

Do you have any of the following conditions?

YES

NO

Diabetes

Thyroid disease (over- or underactive thyroid gland)

Alopecia (hair loss)

Pernicious anaemia (treated by monthly vitamin B injections)

Vitiligo (patches of white skin)

Rheumatoid arthritis

Hayfever /asthma

Do you have any allergies?

Do you have any other skin conditions (e.g. eczema, psoriasis, vitiligo, dry skin, sensitive skin, flaky scalp)?

Are you on any medicines? This includes prescribed/ herbal/ over the                counter/ HRT /contraception. 

If you have already tried treatments for your skin problem, please note them below.

Name of treatment

How long did you use it for?

Effects

Appendix 2: General care of the vulva

Genital skin has less of a barrier than other skin surfaces and is more liable to irritation. Many products, even so-called ‘low-allergy’ products can irritate skin. Perfumed products should be avoided. The vulval area only needs washed once a day

Washing

The vulval area only needs washed once a day. Use a small amount of soap substitute as washing with water on its own tends to cause dry skin. Use your hand, avoiding flannels/sponges or over cleaning, as this will irritate. Do not use a vaginal wash as this is unnecessary and may cause irritation.

  • Dry the skin very gently with a soft towel (no rubbing) or use a hairdryer on a cool setting
  • Do not use soaps, bubble-baths, deodorants or vaginal/baby wipes in or around the vulval area and avoid antiseptics in the bath
  • Shower rather than bathe
  • When washing your hair, avoid allowing the shampoo from coming in to contact with the vulval area
  • Soap substitutes include Emulsifying Ointment, E45, Hydromol, Dermol

Clothing

  • Wear loose fitting, non-coloured cotton or silk underwear and change daily. Dark textile days may irritate the skin
  • Sleep without underwear
  • Wash underwear using non-biological washing detergent and avoid fabric conditioner

Irritants

  • Use unscented unbleached tampons, sanitary pads and panty liners. Avoid plastic coated pads
  • If passing urine makes your symptoms worse, wash the urine away from the vulval area using warm water whilst on the toilet (e.g. using a jug or plastic water bottle)
  • If you suffer from urinary incontinence, please ask your GP to prescribe a barrier ointment or spray to protect your skin
  • When swimming or exercising, protect the vulval area with a barrier cream such as emulsifying ointment or hydromol
  • Itching can sometimes be prevented or relieved by just holding the area tightly for several minutes.
  • Avoid wearing nail varnish on finger nails if you tend to scratch.
  • Some over-the-counter products may contain possible irritants e.g. baby/nappy creams, herbal creams and thrush treatments.
  • Aim to use ointments rather than creams as they have less preservatives

Sex

  • If sex is uncomfortable, lubricants such as Sylk (contains kiwi extract) may help
  • Oil based products can cause condoms to break
  • Difficulties with sexual intercourse are common. Please discuss with your doctor

Emollients

These soothe the skin and will rehydrate (moisturise) dry areas. They are usually fragrance-free and less likely to irritate. Used daily they can help relieve symptoms and protect the skin. They can be kept in the fridge and dabbed on to cool and soothe the skin as often as you like.Examples include: Hydromol, Emulsifying Ointment, E45, Dermol, Aveeno, Epaderm

Contacts

The Vulval Pain Society 

Association for Lichen Sclerosus & Vulval Health

Vulval Health Awareness Campaign

Appendix 3: Use of Clobetasol Proprionate (Dermovate, Clobaderm)

Patient Information on the use of Clobetasol Proprionate 0.05% Ointment

You should apply your ointment sparingly (this means half to one finger tip) to the affected area(s).

These are the areas where you have itch/discomfort or notice changes in the skin. Apply the ointment; Once daily for 1 month

Then Alternate (every 2nd) days for 1 month

Then twice a week for 1 month

Then once a week for 1 month

One 30g tube should last at least 3 months. This amount should not cause you to have adverse effects on the treated skin or elsewhere in the body.

If symptoms return after the above course, you can use the ointment every night for 2 weeks to treat the flare-up and then try to reduce the frequency, as above.

If symptoms keep coming back quickly when you stop using the ointment, you may prefer to use it regularly once or twice a week long term. Long term use is safe as long as one 30g tube lasts at least 3 months. More than this may cause skin thinning.

It is normal to notice stinging for a few minutes after applying the ointment. However, if you notice stinging in the area for more than 1-2 hours after applying it, you may have become sensitive to it. There may be alternative ointments and you should contact your GP or the clinic for advice.

Editorial Information

Last reviewed: 18/09/2017

Next review date: 30/04/2023

Author(s): Kay McAllister.

Version: 2

Approved By: Gynaecology Clinical Governance Group

Document Id: 313

References

UK National guideline on the Management of Vulval Conditions. Clinical Effectiveness Group of the British Association of Sexual Health and HIV. Feb 2014 (accessed online April 2017)

Vulval Pain Society 

British Society for the Study of Vulval Disease